Compensated Awareness Post View
Disclaimer
PlasmaTech Biopharmaceuticals, Inc. (PTBI) Leverages Platforms to Drive Growth
PlasmaTech Biopharmaceuticals is focused on advancing targeted treatments for the unmet needs of critical patient care through the use of two proprietary platforms, Salt Diafiltration Process (SDP) and Polymer Hydrogel Technology (PHT).
The company’s SDP focuses on the extraction of therapeutic biologics, or biopharmaceutical proteins, from human plasma. Currently, the industry standard for the fractionation of human plasma is the Cohn Cold Ethanol Fractionation Process, which has been in use for over 70 years. PlasmaTech’s patented method features unusually high yields of proteins as compared with the Cohn Process, which makes it particularly valuable in the global plasma protein market. Intravenous Immune Globulin, which contains a broad spectrum of antibodies and is the primary driver for manufacturers using the Cohn Process, is recovered in much greater supply (at least 20 percent more) using the company’s proprietary extraction method.
PlasmaTech’s PHT platform is a patented hydrogel delivery system that uses a unique aqueous pseudoplastic liquid to enable extended delivery of drugs to the mouth and upper gastrointestinal tract.
Through the use of these platforms, the company has been able to develop a robust product pipeline that includes two commercial stage products, as well as multiple products currently in development. MuGard™ is a mucoadhesive rinse that provides a protective coating to prevent trauma to oral mucosae, which are a common complication of cancer chemotherapy or radiation therapy to the head and neck region. ProctiGard™ is a treatment for rectal mucositis, which is a debilitating side effect most commonly associated with the treatments of cervical, colon and prostate cancers.
The company’s two primary platforms provide plenty of room for potential growth in the future. The plasma protein market is estimated to be greater than $12 billion, and continued growth of approximately 10 percent annually puts PlasmaTech in a great position to capitalize on the industry’s eventual replacement of the antiquated Cohn fractionation process. As a critical plasma supply shortage looms, the industry is scrambling to increase yields and address supply constraints, both of which are possible through the use of the company’s unique SDP.
With an increasingly strong strategic position in the plasma protein market and recently approved status for two commercial products, the immediate future appears to be exceedingly bright for PlasmaTech.
For more information, visit www.plasmatechbio.com
